Key result
Ibogaine linked to ~142-fold higher disproportionate reporting for ventricular arrhythmia, comparable to dofetilide.
Why the study?
Studies of Schedule I and unscheduled psychoactive drugs have focused disproportionately on efficacy over safety, making rigorous evaluation of their cardiovascular safety and arrhythmia liability essential.
Are Schedule I psychedelic substances and mitragynine associated with disproportionate reporting of ventricular arrhythmia, cardiac arrest, and QTc-prolongation in the FDA Adverse Event Reporting System?
Observational (n=18,499,626)
Are Schedule I psychedelic substances and mitragynine associated with disproportionate reporting of ventricular arrhythmia, cardiac arrest, and QTc-prolongation in the FDA Adverse Event Reporting System?
FAERS pharmacovigilance data demonstrate that ibogaine and mitragynine carry disproportionate reporting risks for QTc-prolongation and ventricular arrhythmias comparable to or exceeding established proarrhythmic drugs like dofetilide and methadone, underscoring the need for rigorous cardiac safety monitoring as psychedelic drug development accelerates.
Answers are grounded in this paper and cite their sources.
Warrants arrhythmia monitoring in ibogaine or mitragynine users; hypothesis-generating for cardiac safety amid psychedelic development.
Background Several Schedule I substances have demonstrated potential benefits for refractory psychiatric conditions and addiction. Some have been legalized at the state level, while others like kratom (mitragynine) are available over-the-counter in some states and illegal in others. A recent presidential executive order directs certain federal agencies to accelerate development and facilitate access to psychedelic drugs through increased funding and expedited FDA review. Studies investigating the therapeutic potential of these drugs are limited and focused disproportionately on efficacy over safety. Rigorous evaluation of cardiovascular safety, including potential arrhythmia liability, is essential. Methods We analyzed reports from the FDA Adverse Event Reporting System from 2000-2024. involving Schedule 1 and other unscheduled drugs with purported therapeutic potential including 3,4-methylenedioxy-methamphetamine (MDMA), mitragynine, ibogaine, lysergic acid diethylamide (LSD), mescaline, psilocybin, tetrahydrocannabinol (THC), and dimethyltryptamine (DMT). We used FDA-approved drugs (e.g., dofetilide, naltrexone) as quasi-experimental positive and negative controls respectively, then calculated proportional reporting ratios (PRR) for the composite of ventricular arrhythmia and cardiac arrest, ventricular arrhythmia only, and QTc-prolongation. Results Among 18,499,626 unique cases, 61,961 (0.3%) mentioned at least one psychoactive drug of interest. The psychedelic drugs ibogaine, MDA, MDMA, and LSD and the non-psychedelic mitragynine exhibited a significant PRR for ventricular arrhythmia/cardiac arrest; the strongest signals were observed for mitragynine (PRR 8.8; 84/1171 reports), and ibogaine (PRR 38.8; 7/25 reports). When restricting analysis to ventricular arrhythmia alone (excluding potential non-arrhythmic cardiac arrest), the signal remained significant for mitragynine (PRR 4.4, 8/1171 reports) and was markedly higher for ibogaine (PRR 142.0, 5/25 reports), approximately 6-fold higher than dofetilide (PRR 24.0; 533/11,950 reports). This corresponded with QTc-prolongation signals for ibogaine (PRR 121.0; 6/25 reports) and mitragynine (PRR 15.9; 38/1171 reports), which were comparable to dofetilide (PRR 30.9; 771/11,950 reports) and methadone (PRR 12.4; 1428/55,895 reports). MDA, MDA, and LSD did not show ventricular arrhythmia signal, and although MDMA was associated with disproportionate reporting of QTc-prolongation (PRR 9.9; 10/474 reports). Conclusions Ibogaine and mitragynine demonstrated disproportionate reporting of ventricular arrhythmia similar to or exceeding established proarrhythmic drugs. These data suggest that robust cardiac safety evaluations will be a regulatory priority given accelerated development of psychedelic drugs.
No takes yet. Share an insight, caveat, or question.
Krantz et al. (2026) conducted an observational in Cardiac arrhythmia and QTc-prolongation associated with psychoactive drugs (n=18,499,626). Psychoactive drugs (including ibogaine and mitragynine) vs. All other drugs in FAERS during the same time interval (plus positive controls like dofetilide and negative controls like naltrexone) was evaluated on Proportional Reporting Ratio (PRR) for ventricular arrhythmia alone (highlighted for ibogaine) (PRR 142.0, p=<0.05). Ibogaine and mitragynine showed disproportionate reporting for ventricular arrhythmia and QTc-prolongation, comparable to or exceeding dofetilide.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: